Dr. Derek Michael Fine, MD

Dr. Fine practices at Johns Hopkins Hospital Nelson/Harvey Building in Baltimore, Maryland.

Dr. Fine's NPI, 1174559868, was assigned on June 24, 2006. Dr. Fine graduated from The Johns Hopkins University School of Medicine in 1994. Dr. Fine holds Maryland license D52470.

Dr. Fine's primary practice is Johns Hopkins Hospital Nelson/Harvey Building, at 600 N Wolfe St, Baltimore, MD 21287 in Baltimore City. The practice phone is (855) 662-3017.

Dr. Fine's primary practice is Johns Hopkins Hospital Nelson/Harvey Building in Baltimore, Maryland. Dr. Fine is also affiliated with The Johns Hopkins Hospital. The medical group on file is Johns Hopkins University. Dmand AI also links Dr. Fine to 1 more hospital and 2 dialysis centers, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Fine practices, 4 sites in all. Vendor and product names are available with a free account.

Nephrology is Dr. Fine's primary specialty in the NPI Registry, under taxonomy code 207RN0300X. Dr. Fine is board certified in nephrology by the American Board of Internal Medicine. Dmand AI has Dr. Fine's licenses on file in 2 states: Maryland and Florida.

Dmand AI lists acute kidney failure, chronic kidney disease, fluid and electrolyte imbalances, gout, hypercalcemia, kidney cysts and kidney disease among the conditions Dr. Fine treats.

CMS data shows 1,453 Medicare services from Dr. Fine across 12 procedure codes in 2024, for 460 Medicare patients. Medicare paid $124,344 for them.

CMS counts 460 Medicare patients who saw Dr. Fine in 2024. The largest group is 65 to 74, with 184 patients. 75% of them have chronic kidney disease, and 75% have high blood pressure. 33% are also on Medicaid. Their average risk score is 4.79, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Fine's median patient age at 68, with 50% women.

In 2024, Dr. Fine wrote 646 Medicare Part D claims for 103 patients. 72% of them were for generic drugs. CMS names the drug for 472 of them, across 19 drugs with 11 or more claims each, at $107,726 in total drug cost. In 2023, CMS named 293 claims across 12 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 83 out of 100 for Dr. Fine for performance year 2024, reported as part of a group. CMS lists Dr. Fine as offering telehealth.

Dmand AI links 132 papers to Dr. Fine, published from 2004 to 2025. 2020 was the busiest year, with 12. The most frequent topics are HIV Infections, Kidney and Lupus Nephritis. Dr. Fine has published most often in Clin J Am Soc Nephrol. Dr. Fine's most frequent co-authors are Mohamed G. Atta, MD, Michelle Mae Estrella, MD and Lois Johanna Arend, MD.

CMS Open Payments shows 18 general payments to Dr. Fine from 4 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 100% of the total. GlaxoSmithKline, LLC. paid the most, $15,375.

Dmand AI lists 4 awards for Dr. Fine, most recently CMS Stage 1 EHR in 2014.

Dr. Fine graduated from The Johns Hopkins University School of Medicine in 1994. Dr. Fine is a member of ACR.

Dr. Fine is in network with 9 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. HMO plans come from the most carriers, 5. Check the plan with the practice before a visit.